Journal ArticleDOI
Toxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer (LAHNSCC).
Reads0
Chats0
TLDR
The cetuximab group experienced significantly more toxicity--grade ≥3 oral mucositis, skin dermatitis, ≥10% weight loss, and enteral feeding requirement than a matched cisplatin group.About:
This article is published in Radiotherapy and Oncology.The article was published on 2011-01-01. It has received 85 citations till now. The article focuses on the topics: Cetuximab & Mucositis.read more
Citations
More filters
Book ChapterDOI
Head and Neck Tumours
B. Spiessl,O. Scheibe,G. Wagner +2 more
TL;DR: A number of clinical trials of targeted therapies in HNSCC show promise in the control of both advanced loco-regional disease and relapsed/metastatic disease.
Journal ArticleDOI
Current concepts in clinical radiation oncology.
M. Orth,Kirsten Lauber,Maximilian Niyazi,Anna A. Friedl,Minglun Li,Cornelius Maihöfer,Lars Schüttrumpf,Anne Ernst,Olivier M Niemöller,Claus Belka +9 more
TL;DR: In the present review, the current status of radiation-based cancer treatment with particular focus on novel aspects and developments that will influence the field of radiation oncology in the near future is summarized and discussed.
Journal ArticleDOI
Mucositis in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus statements.
Vitaliana De Sanctis,Paolo Bossi,Giuseppe Sanguineti,Fabio Trippa,Daris Ferrari,Almalina Bacigalupo,Carla Ripamonti,Michela Buglione,Stefano Pergolizzi,Johannes A. Langendjik,Barbara A. Murphy,Judith E. Raber-Durlacher,Judith E. Raber-Durlacher,Elvio G. Russi,Rajesh V. Lalla +14 more
TL;DR: This paper presents 13 clusters of statements on prophylaxis and treatment of mucositis that achieved consensus, and concludes that a multidisciplinary approach is mandatory, but there is still no gold-standard protocol that is prominently better than others.
Journal ArticleDOI
Treatment of Older Patients With Head and Neck Cancer: A Review
TL;DR: A comprehensive literature review is performed to better understand and discuss issues related to therapeutic recommendations that are particular to patients 65 years and older with head and neck cancer.
Journal ArticleDOI
Cetuximab: its unique place in head and neck cancer treatment.
Pol Specenier,Jan B. Vermorken +1 more
TL;DR: The addition of cetuximab to platinum-based chemotherapy prolongs survival in patients with recurrent or metastatic SCCHN and should be considered as the standard first line regimen for patients who can tolerate this treatment.
References
More filters
Journal ArticleDOI
Global cancer statistics
TL;DR: A substantial proportion of the worldwide burden of cancer could be prevented through the application of existing cancer control knowledge and by implementing programs for tobacco control, vaccination, and early detection and treatment, as well as public health campaigns promoting physical activity and a healthier dietary intake.
Journal ArticleDOI
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
James A. Bonner,Paul M. Harari,Jordi Giralt,Nozar Azarnia,Dong M. Shin,Roger B. Cohen,Christopher U. Jones,Ranjan Sur,David Raben,Jacek Jassem,Roger Ove,Merrill S. Kies,José Baselga,Hagop Youssoufian,Nadia Amellal,Eric K. Rowinsky,Eric K. Rowinsky,K. Kian Ang +17 more
TL;DR: Treatment of locoregionally advanced head and neck cancer with concomitant high-dose radiotherapy plus cetuximab improves locoreGional control and reduces mortality without increasing the common toxic effects associated with radiotherapy to the head andneck.
Journal ArticleDOI
A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003
Karen K. Fu,Thomas F. Pajak,Andy Trotti,Christopher U. Jones,Sharon A. Spencer,Theodore L. Phillips,Adam S. Garden,John A. Ridge,Jay S. Cooper,K. Kian Ang +9 more
TL;DR: Hyperfractionation and accelerated fractionation with concomitant boost are more efficacious than standard fractionation for locally advanced head and neck cancer.
Journal ArticleDOI
Mechanisms of cutaneous toxicities to EGFR inhibitors.
TL;DR: There is an urgent need for an improved understanding of these toxicities to develop adequate staging systems and mechanistically driven therapies, and to ensure quality of life and consistent antineoplastic therapy.
Journal ArticleDOI
Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study.
Wendt Tg,Gerhard G. Grabenbauer,Claus Rödel,H J Thiel,H Aydin,R Rohloff,T P Wustrow,Heinrich Iro,C Popella,A Schalhorn +9 more
TL;DR: Concomitant CT offered improved disease control and survival in advanced head and neck cancer patients due to increased acute toxicity, more supportive care is demanded when CT is given simultaneously.